Skip to main content
Ayman Saad, MD, Hematology, Columbus, OH, The OSUCCC - James

AymanSaadMD

Hematology Columbus, OH

Hematologic Oncology

Ohio State University.

Dr. Saad is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Saad's full profile

Already have an account?

Education & Training

  • West Virginia University
    West Virginia UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
  • University of Maryland Medical Center Midtown Campus
    University of Maryland Medical Center Midtown CampusResidency, Internal Medicine, 2002 - 2005
  • Ain Shams University Faculty of Medicine
    Ain Shams University Faculty of MedicineClass of 1994

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2024
  • OH State Medical License
    OH State Medical License 2018 - 2024
  • AL State Medical License
    AL State Medical License 2012 - 2018
  • WI State Medical License
    WI State Medical License 2008 - 2013
  • WV State Medical License
    WV State Medical License 2005 - 2009
  • MD State Medical License
    MD State Medical License 2004 - 2005
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
    Ayman Saad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgki...
    Ayman Saad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

  • Protmune, a Next-Generation Graft for GvHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation: 1-Year Safety and Efficacy Phase 1 DataClinically Relevant Abs... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Impact of T-Cell Dose on Gvhd Risk after Allogeneic HLA-Matched PBSC Transplantation 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Professional Memberships

Other Languages

  • Arabic

Hospital Affiliations